SUSTAIN trial programme: difference between revisions
Diff·revision 3 → 4·20:33, 14 Aug 2024
Difference between revision 3 and revision 4 of SUSTAIN trial programme. 3 lines changed; the page grew by 625 bytes.
| Revision 3 — 21:36, 2 Aug 2024 ForestPlotFinn (talk) add the run-in period, which changes how the baseline reads 1,946 bytes +732 | Revision 4 — 20:33, 14 Aug 2024 EndpointEnid (talk) add the missing-data handling method 2,571 bytes +625 | ||
|---|---|---|---|
| 10 | Across the programme, semaglutide 1.0 mg reduced glycated haemoglobin by roughly 1.5–1.8 percentage points from baseline, with weight reduction of about 4–6 kg — substantially less than the 2.4 mg obesity dose studied in [[STEP trial programme|STEP]].{{r|sorli2017}} | 10 | Across the programme, semaglutide 1.0 mg reduced glycated haemoglobin by roughly 1.5–1.8 percentage points from baseline, with weight reduction of about 4–6 kg — substantially less than the 2.4 mg obesity dose studied in [[STEP trial programme|STEP]].{{r|sorli2017}} |
| 11 | 11 | ||
| + | 12 | SUSTAIN 6 was the cardiovascular safety trial, randomising 3,297 people with type 2 diabetes at high cardiovascular risk. It reported a hazard ratio of 0.74 (95% CI 0.58–0.95) for the primary composite outcome, a result which — being from a trial designed to demonstrate non-inferiority — is generally described as hypothesis-generating for superiority.{{r|marso2016s}} | |
| + | 13 | ||
| 12 | == Structure of the programme == | 14 | == Structure of the programme == |
| 13 | | Trial | Comparator | Principal finding | | 15 | | Trial | Comparator | Principal finding | |
| ⋮ | ⋮ | ||
| 25 | {{reflist}} | 27 | {{reflist}} |
| 26 | <ref name="sorli2017">Sorli C, Harashima SI, Tsoukas GM, et al. "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes (SUSTAIN 1)." ''The Lancet Diabetes & Endocrinology'' 5(4):251–260 (2017). PMID 28110911.</ref> | 28 | <ref name="sorli2017">Sorli C, Harashima SI, Tsoukas GM, et al. "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes (SUSTAIN 1)." ''The Lancet Diabetes & Endocrinology'' 5(4):251–260 (2017). PMID 28110911.</ref> |
| + | 29 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). DOI:10.1056/NEJMoa1607141. PMID 27633186.</ref> | |
| 27 | 30 | ||
| 28 | {{DEFAULTSORT:SUSTAIN trial programme}} | 31 | {{DEFAULTSORT:SUSTAIN trial programme}} |